Skip to main content

Advertisement

Table 1 Clinical and pathological characteristics, hormonal receptor status, stages, and adjuvant chemotherapy of all patients grouped as <35 years (group 1), between 35–50 years (group 2) and >50 years (group 3).

From: Effects of young age at presentation on survival in breast cancer

Variable Group1 = <35 Group2 = 35–49 Group3 = >50 Total P value
Tumor size<2 cm 16 (15.7%) 95 (20.0%) 115 (18.8%) 1191 0.877
Tumor 2–5 cm 70 (68.6%) 315 (66.1%) 407 (66.4%)   
> 5 cm 16 (15.7%) 66 (13.9%) 91 (14.8%)   
Lymph Node Positive 70 (68.6%) 317 (66.7%) 378 (61.6 %) 1191 0.131
Positive hormone Receptors (estrogen and/or progesterone) 73 (71.6%) 321 (67.6%) 482 (78.5%) 876/1191 <0.001
Grade I 5 (4.9%) 49 (10.3%) 79 (12.9%) 1191 0.019
Grade II 47 (46.1%) 226 (47.6%) 315 (51.3%)   
Grade III 50 (49%) 200 (42.1%) 220 (35.8%)   
Stage I 12 (11.2%) 74 (14.8%) 96 (14.6%) 182 (14.4%) 0.619
Stage II 63 (58.9%) 305 (61.1%) 389 (59.1%) 757 (59.9%)  
Stage III 27 (25.2%) 96 (19.2%) 129 (19.7%) 252 (20.0%)  
Stage IV** 5 (4.7%) 24 (4.8%) 44 (6.6%) 72 (5.7%)  
Adjuvant Chemotherapy 78 (76.5%) 346 (72.8%) 326 (53.1%) 750/1191 <0.001
Adjuvant Anthracycline* 42 (56.0%) 228 (68.3%) 163 (50.6%) 443/731 <0.001
Development of metastasis 33 (32.4%) 109 (22.9%) 140 (22.8%) 282/1191 0.098